10-Q · May 12, 2026
Orchestra BioMed's Q1 2026 results reflect a decrease in total revenue (down 87% YoY), primarily due to the termination of the Terumo Agreement leading to a complete halt of partnership revenue. Gross margin improved to…
Earnings analysis · 10-Q
OBIO earnings analysis
Filed August 10, 2026 · Our reading of the company's report
The latest report
The provided extract is limited to controls, legal proceedings, risk factors, and other information and does not include the income statement, balance sheet, cash flow statement, segment results, or MD&A. Accordingly,…
Read full summary
The provided extract is limited to controls, legal proceedings, risk factors, and other information and does not include the income statement, balance sheet, cash flow statement, segment results, or MD&A. Accordingly, current-quarter revenue, margins, EPS, cash flow, liquidity, and working-capital trends cannot be assessed from the supplied filing text. Controls were deemed effective as of June 30, 2026, no material legal proceedings were reported, and management stated that risk factors were unchanged from the 2025 10-K.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Disclosure controls effective
Management concluded that disclosure controls and procedures were effective as of June 30, 2026.
-
No material control changes
The company reported no change during the quarter ended June 30, 2026 that materially affected, or was reasonably likely to materially affect, internal control over financial reporting.
-
No material legal proceedings
The company said it was not currently a party to any material legal proceedings and was not aware of any pending or threatened proceeding expected to materially affect the business, operating results, or financial condition.
-
Employee stock plan approved
Stockholders approved the 2026 Employee Stock Purchase Plan at the June 23, 2026 annual meeting.
-
CFO trading plan terminated
The CFO terminated a Rule 10b5-1 arrangement on May 27, 2026 covering sales of up to 84,000 shares; no shares had been sold under the arrangement at termination.
What to watch
-
Risk disclosures unchanged
The filing directs investors to the risk factors in Part I, Item 1A of the 2025 10-K and states that there have been no material changes. The provided extract does not quantify the underlying risks.
-
Controls cannot ensure zero errors
The company cautions that its control systems provide only reasonable, not absolute, assurance and may not prevent all errors or fraud; management cited resource constraints as an inherent limitation.
-
Equity-plan disclosure
The CFO's terminated Rule 10b5-1 plan had authorized sales of up to 84,000 shares, although no shares were sold before termination.
Management's outlook
The provided 10-Q extract contains no quantitative revenue, EPS, liquidity, or operating outlook. It states that risk factors are incorporated from the 2025 10-K and does not provide numeric guidance.
Earlier filings 4
10-K · March 12, 2026
Orchestra BioMed positions itself as a partnership‑enabled biomedical company, advancing two flagship candidates (AVIM Therapy with Medtronic and Virtue SAB) through pivotal trials while sharing development and…
10-Q · November 12, 2024
Orchestra BioMed reported Q3 revenue of $987,000 (up from $419,000 in the year-ago quarter), driven by partnership revenue of $803,000 and product revenue of $184,000. Gross margin remained high at ~93.1% while…
10-Q · May 13, 2024
Orchestra BioMed reported total revenue of $620,000 for the three months ended March 31, 2024, down from $1,164,000 in the prior-year quarter, while net loss widened to $13,463,000 (EPS of -$0.38) though EPS slightly…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.